Will NewLink Genetics’ IDO Inhibitor Improve the Efficacy of AstraZeneca’s Checkpoint Inhibitor in Treating Pancreatic Cancer?
September 28, 2017
0
AstraZeneca’s (AZN) checkpoint PD-L1 inhibitor Imfinzi and NewLink Genetics’ (NLNK) IDO inhibitor indoximod will be combined and tested in Phase 2 randomized, placebo-controlled clinical trials together with the standard of care chemotherapy treatment for metastatic pancreatic cancer. AstraZeneca and NewLink Genetics will jointly fund the phase 2 trial of the combination that NewLink will be sponsoring It is a Phase 2 trial that will be …